Alert: Rating Downgrade (1/12/24)-Astrazeneca PLC (NASDAQ: AZN).

out_logo_500#22730.jpg

Stock Rating Downgrade

In recent days the Value Trend Rating for Astrazeneca PLC (NASDAQ: AZN) weakened from C to D reflecting eroding fundamentals and low Appreciation Potential.

out_mm#22730.jpg

Recent Price Action

Astrazeneca PLC (NASDAQ: AZN) stock rose modestly by 0.3% on 1/12/24. The stock closed at $69.42. However, this advance was accompanied by unusually low trading volume at 66% of normal. The stock has risen 0.9% during the last week but has been weak relative to the market over the last nine months.

Current PriceTarget Research Rating

AZN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.

Astrazeneca has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Astrazeneca has a neutral Appreciation Score of 44 but a poor Power Rating of 23, triggering the Negative Value Trend Rating.

Be the first to comment

Leave a Reply

Your email address will not be published.


*